Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
UTI Medium Duration Fund - Regular Plan - Monthly IDCW
★★★★★ TopFund est.
TopFund Score (fallback rating)
- Calculated by: TopFund — used only when no third-party rating exists for this fund
- Formula: 3-year trailing return percentile within category, adjusted ±1 star for expense ratio
- Refresh frequency: Whenever TopFund re-syncs this fund's data
- Limitations: A simplified 2-factor estimate, not equivalent to a rating agency's full analysis
TopFund Score: 51/100 · Average
How this score is calculated
- Star rating (35%)3/5
- 3Y CAGR (30%)6.17%
- Expense ratio (20%)1.29%
- AUM (15%)₹302 Cr
Not investment advice — an analytical read of public fund data. Methodology →
UTI Mutual Fund · Income/Debt Oriented · Medium Term Fund
₹13.84
AUM: ₹302 Cr
NAV updated 10 days ago
Plan
Regular
Option
Idcw
Risk
Moderate
Expense Ratio
1.29%
Exit Load
Nil
Fund Manager
Amandeep Chopra
Inception
Jan 2013
Benchmark
CRISIL Medium to Long Duration Debt A-III Index
Sharpe Ratio
-1.43
Std Dev (1Y)
1.4%
Historical Returns (CAGR)
Annualized trailing returns computed from NAV history — past performance only, not a guarantee of future results.
1m
-0.34%
3m
+0.83%
6m
+2.1%
1y
+4.25%
3y
+6.17%
5y
+5.9%
10y
+2.87%
since inception
+2.87%
TopFund's Take on UTI Medium Duration Fund - Regular Plan - Monthly IDCW
UTI Medium Duration Fund - Regular Plan - Monthly IDCW sits in the middle of the pack for Medium Term Fund funds, currently carrying a 3-star rating. TopFund's composite Health Score, which weighs rating, 3-year CAGR, expense ratio and fund size, puts it at 51/100.
Cost: At 1.29%, the expense ratio runs 74% above the Medium Term Fund category average of 0.74%. That gap is worth weighing against the fund's actual performance versus cheaper peers before committing to a long SIP.
Risk-adjusted performance: Over the trailing 1-year period, the fund shows a negative Sharpe ratio of -1.43 — over the past year, returns haven't kept pace with the volatility involved, even before accounting for the risk-free rate. Separately, annualised volatility of 1.4% is on the lower side for a Medium Term Fund fund, suggesting a comparatively smoother ride.
Who should invest: This fund is best suited to investors whose goals and risk appetite align with a Income/Debt Oriented fund.
This is an automated, data-driven analysis based on the fund's own metrics and its category peers — not personalized investment advice. Consult a SEBI-registered advisor before investing.
Sector Allocation
Asset Allocation
Fund Snapshot
Tools & Guides for This Fund
Frequently Asked Questions about UTI Medium Duration Fund - Regular Plan - Monthly IDCW
The current NAV (Net Asset Value) of UTI Medium Duration Fund - Regular Plan - Monthly IDCW is ₹13.84. NAV is updated every business day after market close by AMFI.
1Y: 4.25% · 3Y CAGR: 6.17% · 5Y CAGR: 5.9%
The expense ratio of UTI Medium Duration Fund - Regular Plan - Monthly IDCW is 1.29% per annum. This is the annual fee charged by the fund to manage your investment.
UTI Medium Duration Fund - Regular Plan - Monthly IDCW is managed by Amandeep Chopra at UTI Mutual Fund.
UTI Medium Duration Fund - Regular Plan - Monthly IDCW is classified as a Moderate risk fund. It is suitable for investors with a moderate risk appetite.
UTI Medium Duration Fund - Regular Plan - Monthly IDCW is a Medium Term Fund fund. SIP suitability depends on your investment goal and risk profile.
You can start a SIP in UTI Medium Duration Fund - Regular Plan - Monthly IDCW with as little as ₹500 per month through most mutual fund platforms. The minimum lump sum investment is typically ₹1,000.
The Assets Under Management (AUM) of UTI Medium Duration Fund - Regular Plan - Monthly IDCW is ₹302 crore. AUM indicates the total market value of assets managed by the fund.
* Past performance is not indicative of future results. Mutual fund investments are subject to market risks.
Discussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.